Today P+F Products + Features GmbH announced that the first implantation of its Breakthrough technology, the TricValve® Transcatheter Bicaval Valves System, was recently performed under the guidance of Samir Kapadia MD, Interventional Cardiologist and Chairman, Dept. of Cardiovascular Medicine and Rishi Puri MD PhD, Interventional Cardiologist, at Cleveland Clinic, Ohio, USA. The successful procedure in a patient with longstanding severe tricuspid regurgitation and right heart failure was performed under conscious sedation and TTE guidance.
“It’s a great pleasure and honor to perform the first Tricvalve implantation in US at such an outstanding institution as the Cleveland Clinic together with the amazing team of Drs. Samir Kapadia and Rishi Puri,” stated Dr. Katharina Kiss, CEO of the company.
The TricValve® Transcatheter Bicaval Valves is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux.
“For our patients with tricuspid regurgitation and systemic congestion with no other options, this procedure can provide a new treatment option, ” states Dr. Samir Kapadia.
“We look forward to further studying this device in the future and testing it versus medical therapy.” according to Dr. Rishi Puri.
Among others, Dr. Rishi Puri performs consulting activities on behalf of P+F Products + Features GmbH.
About the TricValve® Transcatheter Bicaval Valves System
The two dedicated bioprostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve.
They are especially intended for use in patients at extreme risk or who are inoperable for open heart surgical therapy. P+F uses exclusivly it’s proprietary “Dry Pericardium”, which enables the TricValve® Transcatheter Bicval Valves System to come fully pre-mounted, thus facilitating the use of this innovative device in daily clinical practice.
P+F is a leading European company in structural heart disease. With more than 25 years of experience in the medical field, the leadership team of P+F has built up a complete infrastructure for research, development, manufacture, and distribution in order to deliver significant innovations and add value to its customers and patients. P+F is striving to become the “standard of comparison” in the development of state-of-the-art innovative technologies in the field of cardiology.
The further pipeline includes transcatheter biological heart valves like the TAVI system Vienna Aortic Self-Expandable Transcatheter Valve, a Pulmonary Valve and Mitral Valve as well as Aortosave®, a minimally invasive device to treat Type A aortic dissections, as well as the full portfolio of endovascular grafts. The proprietary Dry Pericardium technology platform enables off the shelf use of the company’s heart valves.
Headquartered in Vienna, Austria, P+F has different production sites in Europe, Asia and Brazil. Worldwide operations are coordinated by Dr. Katharina Kiss, CEO, and Dr. Siegfried Einhellig, President and COO. P+F has recently entered into Joint Ventures with OrbusNeich® for the APAC region as well as with Relisys Medical Devices Ltd. for the Indian subcontinent and neighbouring countries.
For more information, please visit https://productsandfeatures.com.
P+F Products and Features GmbH
Argelsrieder Feld 1a
82334 Wessling
Telefon: 081539970390
http://www.productsandfeatures.com
Telefon: +4981539970930
E-Mail: meinhellig@productsandfeatures.com
